These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 21839418)

  • 41. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies.
    Drummond M; Manca A; Sculpher M
    Int J Technol Assess Health Care; 2005; 21(2):165-71. PubMed ID: 15921055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.
    Latimer NR
    Med Decis Making; 2013 Aug; 33(6):743-54. PubMed ID: 23341049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.
    Angelis A; Lange A; Kanavos P
    Eur J Health Econ; 2018 Jan; 19(1):123-152. PubMed ID: 28303438
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.
    Chen W; Jiang Z; Shao Z; Sun Q; Shen K
    Value Health; 2009; 12 Suppl 3():S82-4. PubMed ID: 20586989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How is evidence on test performance synthesized for economic decision models of diagnostic tests? A systematic appraisal of Health Technology Assessments in the UK since 1997.
    Novielli N; Cooper NJ; Abrams KR; Sutton AJ
    Value Health; 2010 Dec; 13(8):952-7. PubMed ID: 21029247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Budget impact analysis.
    Leelahavarong P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Health economic evaluations using decision analytic modeling. Principles and practices--utilization of a checklist to their development and appraisal.
    Soto J
    Int J Technol Assess Health Care; 2002; 18(1):94-111. PubMed ID: 11987445
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities.
    Van Vlaenderen I; Canon JL; Cocquyt V; Jerusalem G; Machiels JP; Neven P; Nechelput M; Delabaye I; Gyldmark M; Annemans L
    Acta Clin Belg; 2009; 64(2):100-12. PubMed ID: 19432022
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
    Ijzerman MJ; Steuten LM
    Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Case studies that illustrate disinvestment and resource allocation decision-making processes in health care: a systematic review.
    Polisena J; Clifford T; Elshaug AG; Mitton C; Russell E; Skidmore B
    Int J Technol Assess Health Care; 2013 Apr; 29(2):174-84. PubMed ID: 23514665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. How much will Herceptin really cost?
    Barrett A; Roques T; Small M; Smith RD
    BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reviewing the evidence to inform the population of cost-effectiveness models within health technology assessments.
    Kaltenthaler E; Tappenden P; Paisley S
    Value Health; 2013; 16(5):830-6. PubMed ID: 23947977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A systematic review of health technology assessment tools in sub-Saharan Africa: methodological issues and implications.
    Kriza C; Hanass-Hancock J; Odame EA; Deghaye N; Aman R; Wahlster P; Marin M; Gebe N; Akhwale W; Wachsmuth I; Kolominsky-Rabas PL
    Health Res Policy Syst; 2014 Dec; 12():66. PubMed ID: 25466570
    [TBL] [Abstract][Full Text] [Related]  

  • 55. AN INTEGRATED PERSPECTIVE ON THE ASSESSMENT OF TECHNOLOGIES: INTEGRATE-HTA.
    Wahlster P; Brereton L; Burns J; Hofmann B; Mozygemba K; Oortwijn W; Pfadenhauer L; Polus S; Rehfuess E; Schilling I; van der Wilt GJ; Gerhardus A
    Int J Technol Assess Health Care; 2017 Jan; 33(5):544-551. PubMed ID: 28756780
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nutrition and health technology assessment: when two worlds meet.
    Poley MJ
    Front Pharmacol; 2015; 6():232. PubMed ID: 26539116
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology.
    Inotai A; Pékli M; Jóna G; Nagy O; Remák E; Kaló Z
    BMC Health Serv Res; 2012 Sep; 12():332. PubMed ID: 22999574
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness analysis and formulary decision making in England: findings from research.
    Williams IP; Bryan S
    Soc Sci Med; 2007 Nov; 65(10):2116-29. PubMed ID: 17698271
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transferability of model-based economic evaluations: the case of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands.
    Essers BA; Seferina SC; Tjan-Heijnen VC; Severens JL; Novák A; Pompen M; Oron UH; Joore MA
    Value Health; 2010; 13(4):375-80. PubMed ID: 20088894
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of health technology assessment in shaping the benefits package in The Netherlands.
    Stolk EA; de Bont A; van Halteren AR; Bijlmer RJ; Poley MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):85-94. PubMed ID: 19371181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.